New hope for young transplant patients: Steroid-Free GVHD treatment explored
NCT ID NCT06695507
First seen Feb 28, 2026 · Last updated May 19, 2026 · Updated 11 times
Summary
This study tested whether the drug ruxolitinib could be used as the first treatment for chronic graft-versus-host disease (cGVHD) in children and young adults, instead of the usual high-dose steroids. cGVHD is a serious complication after a stem cell transplant where the donor cells attack the patient's body. The goal was to see if ruxolitinib alone could control the disease and reduce the need for steroids. However, the study was terminated early after enrolling only 1 participant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
Conditions
Explore the condition pages connected to this study.